You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Authors

  • Anders Handrup Kverneland Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Christopher Aled Chamberlain National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Troels Holz Borch Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Morten Nielsen Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Sofie Kirial Mørk Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Julie Westerlin Kjeldsen Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Cathrine Lund Lorentzen Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Lise Pyndt Jørgensen Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Lene Buhl Riis Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Christina Westmose Yde Department of Clinical Genetics, Kennedy Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Glostrup, Denmark PubMed articlesGoogle scholar articles
  • Özcan Met National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Marco Donia Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Inge Marie Svane Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark PubMed articlesGoogle scholar articles

Citation

Kverneland AH, Chamberlain CA, Borch TH, et al
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
Journal for ImmunoTherapy of Cancer 2021;9:e003499. doi: 10.1136/jitc-2021-003499
Online issue publication 
June 27, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.